Skip to main content
Erschienen in: Medical Oncology 11/2019

01.11.2019 | Original Paper

Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells

verfasst von: Lufeng Zhao, Zipu Yu, Baiqin Zhao

Erschienen in: Medical Oncology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

The vasoactive intestinal peptide receptor-1(VIPR1) has prominent growth effects on a number of common neoplasms. However, there were contradictions in the effect cross different cancers. We aimed to explore the effect of VIPR1 overexpression on a human lung adenocarcinoma cell line H1299. GEO dataset was used to screen differentially expressed genes in lung adenocarcinoma tissues. The expression of VIPR1 mRNA was determined in the cancer Genome Atlas (TCGA). Immunohistochemical analysis was performed to determine VIPR1 protein expression in lung adenocarcinoma and corresponding adjacent tissues (n = 22). Fluorescence real-time quantitative PCR detected the expression of VIPR1 in human normal lung epithelial cell line BEAS-2B and lung adenocarcinoma cell line H1299. Overexpression strategies were employed to assess functions of VIPR1 expression on several malignant phenotypes in H1299. The expression of VIPR1 was lower in lung adenocarcinoma tissues than that in adjacent tissues. Compared with the normal lung epithelial cells BEAS-2B, VIPR1 was down-regulated in lung cancer cells H1299 (P < 0.05). After the overexpression of VIPR1, we found that VIPR1 significantly inhibited growth, migration, and invasion of H1299 cells (P < 0.05). Our findings point out the tumor suppressor roles of VIPR1 in human LUAD pathogenesis.
Literatur
4.
Zurück zum Zitat Zhu LX, Li CY, Shi QY, Ji CF. Effect of iontophoretic 5-HT on raphe-spinal neurons. Acta Pharmacol Sin. 1986;7(5):394–8. Zhu LX, Li CY, Shi QY, Ji CF. Effect of iontophoretic 5-HT on raphe-spinal neurons. Acta Pharmacol Sin. 1986;7(5):394–8.
7.
Zurück zum Zitat Moody TW, Leyton J, Chan D, Brenneman DC, Fridkin M, Gelber E, Levy A, Gozes I. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res Treat. 2001;68(1):55–64.CrossRef Moody TW, Leyton J, Chan D, Brenneman DC, Fridkin M, Gelber E, Levy A, Gozes I. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res Treat. 2001;68(1):55–64.CrossRef
12.
Zurück zum Zitat Collado B, Carmena MJ, Sanchez-Chapado M, Ruiz-Villaespesa A, Bajo AM, Fernandez-Martinez AB, Varga JL, Schally AV, Prieto JC. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int J Oncol. 2005;26(6):1629–35. https://doi.org/10.3892/ijo.26.6.1629.CrossRefPubMed Collado B, Carmena MJ, Sanchez-Chapado M, Ruiz-Villaespesa A, Bajo AM, Fernandez-Martinez AB, Varga JL, Schally AV, Prieto JC. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int J Oncol. 2005;26(6):1629–35. https://​doi.​org/​10.​3892/​ijo.​26.​6.​1629.CrossRefPubMed
14.
Zurück zum Zitat Fruhwald MC, O’Dorisio MS, Fleitz J, Pietsch T, Reubi JC. Vasoactive intestinal peptide (VIP) and VIP receptors: gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood. Int J Cancer. 1999;81(2):165–73.CrossRef Fruhwald MC, O’Dorisio MS, Fleitz J, Pietsch T, Reubi JC. Vasoactive intestinal peptide (VIP) and VIP receptors: gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood. Int J Cancer. 1999;81(2):165–73.CrossRef
Metadaten
Titel
Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells
verfasst von
Lufeng Zhao
Zipu Yu
Baiqin Zhao
Publikationsdatum
01.11.2019
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 11/2019
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-019-1312-y

Weitere Artikel der Ausgabe 11/2019

Medical Oncology 11/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.